Seyedifar, Meysam, Fatemi, Behzad, Soleymani, Fatemeh, Sabouri, Menhajuddin. (1403). Regorafenib versus Cetuximab plus Irinotecan in Third-line Metastatic Colorectal Cancer in Iran: A Model-based Cost-utility Analysis. سامانه مدیریت نشریات علمی, 15(4), 324-332. doi: 10.30476/mejc.2024.100077.1969
Meysam Seyedifar; Behzad Fatemi; Fatemeh Soleymani; Menhajuddin Sabouri. "Regorafenib versus Cetuximab plus Irinotecan in Third-line Metastatic Colorectal Cancer in Iran: A Model-based Cost-utility Analysis". سامانه مدیریت نشریات علمی, 15, 4, 1403, 324-332. doi: 10.30476/mejc.2024.100077.1969
Seyedifar, Meysam, Fatemi, Behzad, Soleymani, Fatemeh, Sabouri, Menhajuddin. (1403). 'Regorafenib versus Cetuximab plus Irinotecan in Third-line Metastatic Colorectal Cancer in Iran: A Model-based Cost-utility Analysis', سامانه مدیریت نشریات علمی, 15(4), pp. 324-332. doi: 10.30476/mejc.2024.100077.1969
Seyedifar, Meysam, Fatemi, Behzad, Soleymani, Fatemeh, Sabouri, Menhajuddin. Regorafenib versus Cetuximab plus Irinotecan in Third-line Metastatic Colorectal Cancer in Iran: A Model-based Cost-utility Analysis. سامانه مدیریت نشریات علمی, 1403; 15(4): 324-332. doi: 10.30476/mejc.2024.100077.1969


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب